Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) was featured on Good Morning America on Nov 3, 2025 for its investigational gene therapy OPGx-LCA5 targeting LCA5-related inherited retinal disease. The segment highlighted participant Lindsey Rambo and described the therapy's approach of delivering a functional LCA5 gene to retinal cells to restore photoreceptor function and partial vision.
The story coincides with ongoing Phase 1/2 trials, multiple active clinical programs for LCA5 and BEST1, a newly activated site at the Retina Foundation of the Southwest, and support from RD Fund and Foundation Fighting Blindness.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IRD declined 6.96%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $134M at that time.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs), announced today that its pioneering work was featured on Good Morning America (ABC News) in honor of World Blindness Awareness Month.
The national feature highlighted the story of Lindsey Rambo, the second participant in Opus Genetics’ ongoing Phase 1/2 trial of gene therapy OPGx-LCA5, aimed at restoring vision for people living with a rare genetic form of blindness caused by mutations in the LCA5 gene, which encodes lebercilin, a protein essential for photoreceptor structure.
The GMA segment, titled “Gene therapy offers hope for blindness,” explores how Opus Genetics’ investigational gene therapy is helping individuals born blind regain partial sight, an unprecedented step forward for the IRD community. The story brings national attention to the life-changing potential of gene therapy and the scientists and patients driving progress in the fight against inherited blindness.
“We are deeply honored to have Opus Genetics and Lindsey’s story featured on Good Morning America,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “For the millions affected by inherited retinal diseases, these advancements represent hope. Our mission has always been to strive to bring the most promising gene therapies from the lab to patients as quickly and safely as possible.”
“Taking part in this study has given me hope not just for myself, but for people living with inherited blindness,” said Lindsey Rambo, the second participant in the Opus Genetics LCA5 clinical trial. “Being featured on Good Morning America and sharing my experience means helping others understand that research like this can potentially change lives.”
By delivering a functional copy of the defective gene directly to retinal cells, Opus Genetics’ approach aims to restore the function of light-sensing photoreceptors and, ultimately, vision itself.
The gene therapy featured on Good Morning America was made possible by Opus Genetics, with support from the Retinal Degeneration (RD) Fund and the Foundation Fighting Blindness.
The GMA feature coincides with Opus Genetics’ growing clinical and community momentum, including multiple ongoing trials for LCA5 and BEST1 gene therapies, a newly activated site at the Retina Foundation of the Southwest.
Watch the full Good Morning America feature here: https://www.goodmorningamerica.com/video/127055565
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, expectations regarding us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, and our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive”, “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. Opus Genetics’ pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
What did Opus Genetics (IRD) announce on Good Morning America on Nov 3, 2025?
What is OPGx-LCA5 and how does it work in Opus Genetics' IRD trial (IRD)?
Which clinical programs did Opus Genetics note in the Nov 3, 2025 announcement (IRD)?
Who supported the Good Morning America feature about Opus Genetics (IRD)?
Does the Good Morning America feature report regulatory approval for Opus Genetics' OPGx-LCA5 (IRD)?
How can investors watch the Opus Genetics Good Morning America feature mentioned on Nov 3, 2025 (IRD)?
